Yes, Inotropic Agents Can Cause Supraventricular Tachycardia
Inotropic agents are well-documented to cause supraventricular tachycardia (SVT), with the primary mechanisms being increased automaticity, enhanced AV nodal conduction, and elevated intracellular calcium concentrations that promote arrhythmogenesis. This is a recognized adverse effect that requires continuous ECG monitoring during inotrope infusion.
Mechanism and Evidence
The arrhythmogenic potential of inotropes stems from their fundamental mechanism of action. By elevating myocyte calcium concentrations to enhance contractility, these agents simultaneously create conditions favorable for arrhythmia development 1. The ESC Heart Failure Guidelines explicitly warn that "infusion of most inotropes is accompanied by an increased incidence of both atrial and ventricular arrhythmias" and specifically note that "in patients with AF, dobutamine/dopamine may facilitate conduction through the AV node and lead to tachycardia" 2.
Specific Inotropic Agents and SVT Risk
Dobutamine and Dopamine
- Dobutamine increases sinoatrial node automaticity and decreases both atrial and AV node refractoriness, directly facilitating SVT 1
- Dopamine increases conduction through the AV node and has been documented to induce both atrial and ventricular arrhythmias 1
- A case report documents dopamine-induced paroxysmal SVT in an infant, suggesting particular vulnerability in certain populations 3
- Dopamine produces greater elevations in heart rate at a given cardiac index compared to dobutamine 1
Phosphodiesterase Inhibitors
- Milrinone and amrinone increase AV nodal conduction and decrease atrial refractoriness 1
- These agents can cause sinus tachycardia and have been associated with SVT, though the incidence appears lower than with catecholamines 1
Clinical Implications and Monitoring
The ESC guidelines mandate continuous clinical monitoring and ECG telemetry during inotrope infusion 2. This is not optional—it's a requirement based on the established arrhythmogenic risk.
Key monitoring considerations:
- Patients with atrial fibrillation are at particular risk, as inotropes facilitate AV nodal conduction and can precipitate rapid ventricular rates
- The arrhythmogenic effects are dose-dependent, with higher doses carrying greater risk 1
- Patients with underlying arrhythmias, heart failure, or those receiving excessive doses face the highest proarrhythmic risk 1
Paradoxical Use in Electrophysiology
Interestingly, the arrhythmogenic properties of inotropes are exploited therapeutically during electrophysiology studies. Isoproterenol (a β-agonist similar to dobutamine) is specifically used to induce SVT for diagnostic purposes, with a 71% success rate for arrhythmia induction 4. This demonstrates the potent pro-arrhythmic effects of these agents.
Risk Stratification
While clinically significant proarrhythmic effects occur relatively rarely at conventional doses 1, the risk is real and documented. The primary arrhythmias reported are:
- Sinus tachycardia (most common)
- Supraventricular tachycardia
- Ventricular ectopic activity (3-17% of patients)
- Ventricular tachycardia (rare)
Clinical Bottom Line
When using inotropes, anticipate the possibility of SVT. Have adenosine readily available, ensure continuous ECG monitoring is in place, and be prepared to reduce or discontinue the inotrope if significant tachyarrhythmias develop. The benefit of improved hemodynamics must be weighed against the arrhythmogenic risk, particularly in patients with pre-existing arrhythmias or structural heart disease.